{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:32Z","timestamp":1792782872990,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ViiV Healthcare","award":["ViiV Healthcare"],"award-info":[{"award-number":["ViiV Healthcare"]}],"id":[{"id":"https:\/\/ror.org\/01cc9yk21","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NIMH","award":["P30MH136919"],"award-info":[{"award-number":["P30MH136919"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Transgender women and transfeminine people (TWTFP) experience disproportionately high HIV prevalence, low HIV pre-exposure prophylaxis (PrEP) coverage, and negative healthcare experiences. Long-acting injectable PrEP (LAI-PrEP) and daily oral-PrEP are delivered under different healthcare interaction protocols. We examined the role of healthcare-related experiences on willingness and preference for LAI-PrEP among a U.S. nationwide sample of sexually active TWTFP aged 15+. Recruitment occurred between 6\/2022 and 10\/2023 via social media advertisements for a cross-sectional online sexual health survey. Analyses included past-year PrEP na\u00efve TWTFP with no prior HIV diagnosis (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u20091648). Participants reported LAI-PrEP willingness and ranked PrEP modality preferences; recent healthcare-related experiences were explored as correlates, using adjusted multivariable Poisson regression with robust variance estimation. Among respondents, 26.3% were willing to use LAI-PrEP (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009433\/1648). Among participants willing to use LAI-PrEP and another modality (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009390\/433; 90.1%), 45.6% (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009178\/390) preferred LAI-PrEP. Discussing sexual health with a healthcare provider (HCP) was associated with increased LAI-PrEP willingness (adjusted prevalence ratio [aPR]\u2009=\u20091.34; 95% confidence interval [CI]\u2009=\u20091.12\u20131.60;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001); use of oral prescription medication (non-hormonal) was associated with decreased LAI-PrEP willingness (aPR\u2009=\u20090.60; 95% CI\u2009=\u20090.38\u20130.93;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.022). No significant associations were found between healthcare-related experiences and LAI-PrEP preference. Given that most TWTFP who were willing to use LAI-PrEP were also willing to use oral-PrEP, but nearly half preferred LAI-PrEP, offering multiple PrEP modalities is essential to meet their needs. Associations between sexual health discussions and increased LAI-PrEP willingness highlight the importance of HCP engagement; initiatives which encourage HCPs to initiate LAI-PrEP conversations in supportive ways are crucial. Associations between oral prescription use and decreased LAI-PrEP willingness, coupled with null findings related to injection use, highlight the need for further investigation.\n                  <\/jats:p>","DOI":"10.1007\/s10461-025-05016-y","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:43:40Z","timestamp":1769528620000},"page":"2856-2865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of Healthcare-Related Experiences in Willingness and Preference for Long-Acting Injectable PrEP (LAI-PrEP) Among Transfeminine People in the United States"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3323-1983","authenticated-orcid":false,"given":"Jennifer L.","family":"Glick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle F.","family":"Nestadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irah L.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna A.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariah","family":"Valentine-Graves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savannah","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duygu","family":"Islek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Baral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Ragone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"de Ruiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vani","family":"Vannappagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"5016_CR1","unstructured":"Herman JL, Flores AR, O\u2019Neill KK. How many adults and youth identify as transgender in the United States? (2022)"},{"key":"5016_CR2","unstructured":"Centers for Disease C, Prevention. HV surveillance supplemental report: estimated HIV incidence and prevalence in the United States, 2024;2018\u20132022"},{"issue":"5","key":"5016_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048478","volume":"12","author":"EO Murchu","year":"2022","unstructured":"Murchu EO, Marshall L, Teljeur C, et al. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open. 2022;12(5):e048478.","journal-title":"BMJ Open"},{"issue":"10","key":"5016_CR4","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/09540121.2019.1612014","volume":"31","author":"NP de Carvalho","year":"2019","unstructured":"de Carvalho NP, Mendicino CCP, C\u00e2ndido RCF, Alecrim DJD, de P\u00e1dua CAM. HIV pre-exposure prophylaxis (PrEP) awareness and acceptability among trans women: a review. AIDS Care. 2019;31(10):1234\u201340.","journal-title":"AIDS Care"},{"issue":"1","key":"5016_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.15585\/mmwr.su7301a2","volume":"73","author":"E Morris","year":"2024","unstructured":"Morris E, Teplinskaya A, Olansky E, Rinderle JK, Chapin-Bardales J. Characteristics associated with pre-exposure prophylaxis discussion and use among transgender women without HIV Infection \u2014 national HIV behavioral surveillance among transgender women, Seven Urban Areas, United States, 2019\u20132020. MMWR Supplements. 2024;73(1):9\u201320.","journal-title":"MMWR Supplements"},{"issue":"5","key":"5016_CR6","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/QAI.0000000000002403","volume":"84","author":"JM Sevelius","year":"2020","unstructured":"Sevelius JM, Poteat T, Luhur WE, Reisner SL, Meyer IH. HIV testing and PrEP use in a national probability sample of sexually active transgender people in the United States. J Acquired Immune Defic Syn. 2020;84(5):437\u201342.","journal-title":"J Acquired Immune Defic Syn"},{"issue":"12","key":"5016_CR7","doi-asserted-by":"publisher","first-page":"26199","DOI":"10.1002\/jia2.26199","volume":"26","author":"EE Cooney","year":"2023","unstructured":"Cooney EE, Saleem HT, Stevenson M, et al. PrEP initiation and discontinuation among transgender women in the United States: A longitudinal, mixed methods cohort study. J Int AIDS Soc. 2023;26(12):26199\u201326199.","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"5016_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/QAI.0000000000002112","volume":"82","author":"T Poteat","year":"2019","unstructured":"Poteat T, Wirtz A, Malik M, et al. A gap between willingness and uptake: findings from mixed methods research on HIV prevention among Black and Latina transgender women. J Acquired Immune Defic Syn. 2019;82(2):131\u2013131.","journal-title":"J Acquired Immune Defic Syn"},{"issue":"8","key":"5016_CR9","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s10461-023-03983-8","volume":"27","author":"K Bruxvoort","year":"2023","unstructured":"Bruxvoort K, Portugal C, Munis M, Pak K, Hechter R. Understanding barriers and facilitators of pre-exposure prophylaxis (PrEP) among transgender and gender diverse adults in an integrated health care system. AIDS Behav. 2023;27(8):2579\u201391.","journal-title":"AIDS Behav"},{"issue":"11","key":"5016_CR10","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1007\/s10461-018-2102-9","volume":"22","author":"CT Rael","year":"2018","unstructured":"Rael CT, Martinez M, Giguere R, et al. Barriers and facilitators to oral PrEP use among transgender women in New York city. AIDS Behav. 2018;22(11):3627\u20133627.","journal-title":"AIDS Behav"},{"issue":"5","key":"5016_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/09540121.2019.1659912","volume":"32","author":"SR Cahill","year":"2020","unstructured":"Cahill SR, Keatley JA, Wade Taylor S, et al. \u201cSome of us, we don\u2019t know where we\u2019re going to be tomorrow.\u201d Contextual factors affecting PrEP use and adherence among a diverse sample of transgender women in San Francisco. AIDS Care. 2020;32(5):585\u201393.","journal-title":"AIDS Care"},{"issue":"5","key":"5016_CR12","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s12325-020-01295-0","volume":"37","author":"KH Mayer","year":"2020","unstructured":"Mayer KH, Agwu A, Malebranche D. Barriers to the wider use of pre-exposure prophylaxis in the United States: a narrative review. Adv Therapy. 2020;37(5):1778\u20131778.","journal-title":"Adv Therapy"},{"issue":"7","key":"5016_CR13","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s10461-021-03159-2","volume":"25","author":"A Ogunbajo","year":"2021","unstructured":"Ogunbajo A, Storholm ED, Ober AJ, et al. Multilevel barriers to HIV PrEP uptake and adherence among Black and Hispanic\/Latinx transgender women in Southern California. AIDS Behav. 2021;25(7):2301\u20132301.","journal-title":"AIDS Behav"},{"issue":"2","key":"5016_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/08964289.2019.1585325","volume":"45","author":"PA D\u2019Avanzo","year":"2019","unstructured":"D\u2019Avanzo PA, Bass SB, Brajuha J, et al. Medical mistrust and PrEP perceptions among transgender women: a cluster analysis. Behav Med. 2019;45(2):143\u201352.","journal-title":"Behav Med"},{"key":"5016_CR15","doi-asserted-by":"publisher","DOI":"10.1089\/lgbt.2017.0093","author":"JL Glick","year":"2018","unstructured":"Glick JL, Theall KP, Andrinopoulos KM, Kendall C. The role of discrimination in care postponement among trans-feminine individuals in the US National Transgender Discrimination Survey. LGBT Health. 2018. https:\/\/doi.org\/10.1089\/lgbt.2017.0093.","journal-title":"LGBT Health"},{"issue":"2","key":"5016_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/01612840.2021.1961330","volume":"43","author":"K Drabish","year":"2022","unstructured":"Drabish K, Theeke LA. Health impact of stigma, discrimination, prejudice, and bias experienced by transgender people: a systematic review of quantitative studies. Issues Mental Health Nurs. 2022;43(2):111\u20138.","journal-title":"Issues Mental Health Nurs"},{"issue":"12","key":"5016_CR17","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/jamia\/ocac142","volume":"29","author":"C Apodaca","year":"2022","unstructured":"Apodaca C, Casanova-Perez R, Bascom E, et al. Maybe they had a bad day: how LGBTQ and BIPOC patients react to bias in healthcare and struggle to speak out. J Am Med Inform Assoc. 2022;29(12):2075\u201382.","journal-title":"J Am Med Inform Assoc"},{"issue":"5","key":"5016_CR18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2105\/AJPH.2012.301069","volume":"103","author":"ML Hatzenbuehler","year":"2013","unstructured":"Hatzenbuehler ML, Phelan JC, Link BG. Stigma as a fundamental cause of population health inequalities. Am J Public Health. 2013;103(5):813\u201321.","journal-title":"Am J Public Health"},{"issue":"5","key":"5016_CR19","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s10461-022-03944-7","volume":"27","author":"AV Rivera","year":"2023","unstructured":"Rivera AV, Lopez JM, Braunstein SL. Exploring the association between gender affirmation and PrEP use among transgender women in New York City. AIDS Behav. 2023;27(5):1523\u20131523.","journal-title":"AIDS Behav"},{"issue":"21","key":"5016_CR20","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1093\/ajhp\/zxac201","volume":"79","author":"C Prather","year":"2022","unstructured":"Prather C, Jeon C. Cabotegravir: the first long-acting injectable for HIV pre-exposure prophylaxis. Am J Health-Syst Pharm. 2022;79(21):1898\u2013905.","journal-title":"Am J Health-Syst Pharm"},{"issue":"7","key":"5016_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595\u2013608.","journal-title":"N Engl J Med"},{"issue":"6","key":"5016_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/hiv.13451","volume":"24","author":"G Liegeon","year":"2023","unstructured":"Liegeon G, Ghosn J. Long-acting injectable cabotegravir for PrEP: a game\u2010changer in HIV prevention? HIV Med. 2023;24(6):653\u201363.","journal-title":"HIV Med"},{"issue":"1","key":"5016_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/COH.0000000000000597","volume":"15","author":"ME Clement","year":"2020","unstructured":"Clement ME, Kofron R, Landovitz RJ. Long-acting injectable cabotegravir for the prevention of HIV infection. Curr Opin HIV AIDS. 2020;15(1):19.","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"5016_CR24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/COH.0000000000000219","volume":"11","author":"RJ Landovitz","year":"2016","unstructured":"Landovitz RJ, Kofron R, McCauley M. The promise and pitfalls of long acting injectable agents for HIV prevention. Curr Opin HIV AIDS. 2016;11(1):122.","journal-title":"Curr Opin HIV AIDS"},{"issue":"4","key":"5016_CR25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/COH.0000000000000733","volume":"17","author":"MA Spinelli","year":"2022","unstructured":"Spinelli MA, Grinsztejn B, Landovitz RJ. Promises and challenges: cabotegravir for preexposure prophylaxis. Curr Opin HIV AIDS. 2022;17(4):186\u201391.","journal-title":"Curr Opin HIV AIDS"},{"issue":"7","key":"5016_CR26","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1007\/s10461-022-03587-8","volume":"26","author":"R Stephenson","year":"2022","unstructured":"Stephenson R, Rogers E, Mansergh G, Hirshfield S, Sullivan P. Intimate partner violence and preferences for pre-exposure prophylaxis (PrEP) modes of delivery among a sample of gay, bisexual, and other men who have sex with men. AIDS Behav. 2022;26(7):2425\u201334.","journal-title":"AIDS Behav"},{"key":"5016_CR27","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1007\/s10508-017-1049-7","volume":"47","author":"KB Biello","year":"2018","unstructured":"Biello KB, Hosek S, Drucker MT, et al. Preferences for injectable PrEP among young US cisgender men and transgender women and men who have sex with men. Arch Sex Behav. 2018;47:2101\u20137.","journal-title":"Arch Sex Behav"},{"key":"5016_CR28","unstructured":"Prevention CfDCa. Preexposure prophylaxis for the prevention of HIV infection in the United States\u20132021 update: a clinical practice guideline. In: Service UPH, (2021)"},{"key":"5016_CR29","unstructured":"World Health O. Guidelines on long-acting injectable cabotegravir for HIV prevention. Geneva (2022)"},{"key":"5016_CR30","doi-asserted-by":"publisher","first-page":"232595822412933","DOI":"10.1177\/23259582241293336","volume":"23","author":"JL Glick","year":"2024","unstructured":"Glick JL, Nestadt DF, Sanchez T, et al. Location preferences for accessing long-acting injectable pre-exposure prophylaxis (LA-PrEP) among men who have sex with men (MSM) currently on daily oral PrEP. J Int Assoc Prov AIDS Care (JIAPAC). 2024;23:23259582241293336.","journal-title":"J Int Assoc Prov AIDS Care (JIAPAC)"},{"issue":"3","key":"5016_CR31","doi-asserted-by":"publisher","first-page":"26077","DOI":"10.1002\/jia2.26077","volume":"26","author":"P Schoenberg","year":"2023","unstructured":"Schoenberg P, Edwards OW, Merrill L, et al. Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021\u20132022: cross-sectional study. J Int AIDS Soc. 2023;26(3):26077\u201326077.","journal-title":"J Int AIDS Soc"},{"key":"5016_CR32","unstructured":"Rosen JG, Beckham SW, Glick JL, et al. Acceptability of event-driven and long-acting HIV pre-exposure prophylaxis formulations among transgender women engaged in street-based sex work in Baltimore, Maryland. Transgender Health, 2022"},{"issue":"1","key":"5016_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/10497323241265943","volume":"35","author":"AR Gordon","year":"2025","unstructured":"Gordon AR, Haiken S, Murchison GR, Ag\u00e9nor M, Hughto JMW, Nelson KM. Long-acting injectable pre-exposure prophylaxis perceptions and preferences among transgender and nonbinary young adults in the United States. Qual Health Res. 2025;35(1):74\u201387.","journal-title":"Qual Health Res"},{"issue":"4","key":"5016_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0320961","volume":"20","author":"D Islek","year":"2025","unstructured":"Islek D, Sanchez T, Baral S, et al. Preferences and willingness for starting daily, on-demand, and long-acting injectable HIV pre-exposure prophylaxis among transfeminine persons in the US, 2022\u20132023. PLoS One. 2025;20(4):e0320961.","journal-title":"PLoS One"},{"issue":"5","key":"5016_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1089\/trgh.2020.0071","volume":"6","author":"M Zlotorzynska","year":"2021","unstructured":"Zlotorzynska M, Sanchez TH, Scheim AI, et al. Transgender women\u2019s internet survey and testing: protocol and key indicators report. Transgend Health. 2021;6(5):256\u201366.","journal-title":"Transgend Health"},{"issue":"1","key":"5016_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/aje\/kwab240","volume":"191","author":"JM Wiginton","year":"2022","unstructured":"Wiginton JM, Murray SM, Augustinavicius J, et al. Metrics of sexual behavior stigma among cisgender men who have sex with men in 9 cities across the United States. Am J Epidemiol. 2022;191(1):93\u2013103.","journal-title":"Am J Epidemiol"},{"issue":"9","key":"5016_CR37","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1007\/s10461-023-04028-w","volume":"27","author":"JM Wiginton","year":"2023","unstructured":"Wiginton JM, Maksut JL, Scheim AI, Zlotorzynska M, Sanchez TH, Baral SD. Intersecting sexual behavior and gender identity stigmas among transgender women in the United States: burden and associations with sexual health. AIDS Behav. 2023;27(9):3064\u201379.","journal-title":"AIDS Behav"},{"issue":"2","key":"5016_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/JNC.0000000000000384","volume":"34","author":"E Kamitani","year":"2023","unstructured":"Kamitani E, Wichser ME, Mizuno Y, DeLuca JB, Higa DH. What factors are associated with willingness to use HIV pre-exposure prophylaxis (PrEP) among U.S. men who have sex with men not on PrEP? A systematic review and meta-analysis. J Assoc Nurses AIDS Care. 2023;34(2):135\u201345.","journal-title":"J Assoc Nurses AIDS Care"},{"issue":"3","key":"5016_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26077","volume":"26","author":"P Schoenberg","year":"2023","unstructured":"Schoenberg P, Edwards OW, Merrill L, et al. Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021\u20132022: cross\u2010sectional study. J Int AIDS Soc. 2023;26(3):e26077.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"5016_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/EDE.0000000000001544","volume":"34","author":"D Talbot","year":"2023","unstructured":"Talbot D, M\u00e9sidor M, Chiu Y, Simard M, Sirois C. An alternative perspective on the robust Poisson method for estimating risk or prevalence ratios. Epidemiology. 2023;34(1):1\u20137.","journal-title":"Epidemiology"},{"issue":"6","key":"5016_CR41","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4097\/kja.19087","volume":"72","author":"JH Kim","year":"2019","unstructured":"Kim JH. Multicollinearity and misleading statistical results. Korean J Anesthesiol. 2019;72(6):558\u201369.","journal-title":"Korean J Anesthesiol"},{"issue":"5","key":"5016_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/09564624231152781","volume":"34","author":"F Teng","year":"2023","unstructured":"Teng F, Sha Y, Fletcher LM, Welsch M, Burns P, Tang W. Barriers to uptake of PrEP across the continuum among transgender women: a global scoping review. Int J STD AIDS. 2023;34(5):299\u2013314.","journal-title":"Int J STD AIDS"},{"issue":"6","key":"5016_CR43","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1089\/apc.2021.0236","volume":"36","author":"M Dang","year":"2022","unstructured":"Dang M, Scheim AI, Teti M, et al. Barriers and facilitators to HIV pre-exposure prophylaxis uptake, adherence, and persistence among transgender populations in the United States: a systematic review. AIDS Patient Care STDs. 2022;36(6):236\u201348.","journal-title":"AIDS Patient Care STDs"},{"issue":"10","key":"5016_CR44","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s40265-020-01313-z","volume":"80","author":"TC Poteat","year":"2020","unstructured":"Poteat TC, Radix A. HIV antiretroviral treatment and pre-exposure prophylaxis in transgender individuals. Drugs. 2020;80(10):965\u201372.","journal-title":"Drugs"},{"key":"5016_CR45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.socscimed.2013.02.019","volume":"84","author":"T Poteat","year":"2013","unstructured":"Poteat T, German D, Kerrigan D. Managing uncertainty: a grounded theory of stigma in transgender health care encounters. Soc Sci Med. 2013;84:22\u20139.","journal-title":"Soc Sci Med"},{"issue":"10","key":"5016_CR46","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1111\/jan.15323","volume":"78","author":"RAF Velasco","year":"2022","unstructured":"Velasco RAF, Slusser K, Coats H. Stigma and healthcare access among transgender and gender-diverse people: a qualitative meta-synthesis. J Adv Nurs. 2022;78(10):3083\u2013100.","journal-title":"J Adv Nurs"},{"key":"5016_CR47","unstructured":"James SE, Herman JL, Durso LE, Heng-Lehtinen R. Early insights: a report of the 2022 US transgender survey, 2024"},{"issue":"2","key":"5016_CR48","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2105\/AJPH.2016.303582","volume":"107","author":"G Rebchook","year":"2017","unstructured":"Rebchook G, Keatley J, Contreras R, et al. The transgender women of color initiative: implementing and evaluating innovative interventions to enhance engagement and retention in HIV care. Am J Public Health. 2017;107(2):224\u20139.","journal-title":"Am J Public Health"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-05016-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-025-05016-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-05016-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:36:17Z","timestamp":1789634177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-025-05016-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5016"],"URL":"https:\/\/doi.org\/10.1007\/s10461-025-05016-y","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"20 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS, AdR, LR, KB, and VV are employees of ViiV Healthcare and hold stock in GSK as part of their employment.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Activities were approved by the Emory institutional review board- IRB00108784. Participants provided informed consent, via an online survey check box. The study has a waiver of documentation of written consent, given it is an online survey.","order":2,"name":"Ethics","label":"Ethical Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}